Reviewed by Sarah Alter, Ph.D. — Scientific Affairs, OrganaBio. 15 years of immunology research spanning autoimmunity, cancer, and infectious disease. University of Miami Miller School of Medicine. Registered Patent Agent.
What Is NK Cell Expansion From a Leukopak?
NK cell expansion from a leukopak is the ex vivo process of amplifying the natural killer cell population (CD3−CD56+ lymphocytes) from peripheral blood mononuclear cells for research, preclinical testing, and off-the-shelf cell therapy development. Leukopaks are the preferred starting material over whole blood for NK expansion because NK cells represent only 5–15% of circulating PBMCs, and the concentrated cell yield from leukapheresis (2–10 billion PBMCs per collection) provides sufficient starting NK cells for meaningful expansion runs without pooling multiple donors.
NK Cell Biology: What Expansion Preserves and What It Changes
Before designing an expansion protocol, it helps to know which NK cell properties the expansion is supposed to preserve, amplify, or model. Freshly isolated NK cells from peripheral blood are predominantly CD56dimCD16+ cytotoxic NK cells (~90%) with a smaller CD56brightCD16−/lo immunoregulatory subset (~10%). During expansion, the balance can shift depending on the cytokine and feeder conditions used.
KIR repertoire. Killer immunoglobulin-like receptor (KIR) genotype is the most underappreciated variable in NK cell therapy development. KIR genes are highly polymorphic, and the KIR:HLA interaction determines whether NK cells kill or spare target cells through “missing self” recognition. For allogeneic NK programs, donor KIR genotype must be matched or deliberately mismatched with the target patient’s HLA type. OrganaBio is the only supplier that provides KIR genotyping data alongside leukopak lot release documentation. Selecting a KIR-informative donor before expansion is the prerequisite for alloreactive NK programs.
Cytotoxicity markers. Functional NK cytotoxicity depends on the balance of activating receptors (NKp44, NKp46, NKG2D, DNAM-1) and inhibitory receptors (KIR2DL1/2/3, NKG2A/CD94). Expansion conditions that heavily favor one receptor class produce NK cells that behave differently in cytotoxicity assays than freshly isolated cells. Validate receptor expression by flow at the end of expansion before cytotoxicity testing.
NK Cell Expansion Protocol From Leukopak PBMCs
This protocol describes a feeder cell-free cytokine-driven expansion approach, which is the most translatable format for programs developing GMP-compatible processes. Feeder-based methods (K562-mbIL21, etc.) achieve higher fold expansion but introduce regulatory complexity for programs approaching GMP.
Step 1: NK Cell Isolation
Thaw cryopreserved leukopak PBMCs at 37°C, rest 1–2 hours in complete NK medium (RPMI + 10% human AB serum + 2 mM L-glutamine). Isolate NK cells by negative selection: deplete T cells (CD3), B cells (CD19), monocytes (CD14), dendritic cells (CD11c/CD123), and red blood cells (glycophorin A). Target ≥90% CD56+ purity in the CD3− gate. Validate by flow: CD3−CD56+CD16+/−. Typical NK yield from healthy donor: 5–15% of total PBMCs. From disease-state donors, yields vary — SLE donors frequently show reduced NK frequency; cancer donors may have elevated NK numbers from disease-driven homeostatic proliferation.
Step 2: Expansion Culture Setup
Seed isolated NK cells at 0.5–1 × 10⁵ cells/mL in NK expansion medium. Cytokine conditions for feeder-free expansion:
- IL-2 (500–1000 IU/mL): The standard NK survival and proliferation signal. High concentrations expand all NK subsets; lower concentrations are more selective for CD56bright immunoregulatory NK cells.
- IL-15 (10–20 ng/mL): Preferred for memory-like NK differentiation and programs targeting CD56dim effector NK expansion. IL-15 produces lower fold expansion than IL-2 but better preserves cytotoxic phenotype.
- IL-21 (50 ng/mL, optional): Supports NKp44 upregulation and enhances cytotoxic function in combination with IL-15. Use at Day 3–5, not from Day 0, to avoid inducing apoptosis in early culture.
Half-medium changes every 2–3 days. Add fresh cytokines at each change.
Step 3: Expansion Monitoring
Count cells and assess viability every 2–3 days. Typical expansion profile: minimal or negative growth Days 1–3 (adaptation phase), exponential expansion Days 3–14. Target fold expansion at Day 14: 50–500x depending on cytokine conditions and donor. Disease-state donors from inflammatory conditions (RA, SLE, IBD) may show altered expansion kinetics from cytokine pre-conditioning in vivo — account for this when planning cell numbers for downstream assays.
Step 4: Functional Validation
Before cytotoxicity assays, validate the expanded product by flow cytometry: CD3−CD56+CD16+/− (identity), NKG2D, NKp46, KIR expression (function), CD107a degranulation after K562 co-culture (effector function), and intracellular IFN-γ after PMA/ionomycin stimulation. For KIR-informative programs, confirm KIR allele expression matches the donor’s genotype data from the leukopak COA.
Disease-State NK Cells: Why Donor Selection Changes the Biology
NK cells from disease-state donors carry distinct phenotypic and functional signatures that healthy donor cells do not model:
SLE: Peripheral NK cells are numerically reduced in active SLE and show decreased NKp46 and NKG2D expression. Expansion from SLE donors models the NK functional impairment relevant to programs targeting lupus-associated immune dysregulation or using SLE donors as effectors in ADCC assays.
Cancer (NHL, AML, melanoma): NK cells in cancer patients frequently show exhaustion phenotypes (LAG-3+, TIM-3+, reduced CD16) and impaired cytotoxicity from chronic tumor immunosuppression. For off-the-shelf NK therapy development targeting these indications, disease-state donors provide the functionally relevant starting material for understanding how allogeneic NK cells must overcome the tumor microenvironment. Expansion can partially reverse exhaustion, but baseline donor phenotype informs product design.
Rheumatoid Arthritis: NK cells in RA are skewed toward CD56brightCD16lo immunoregulatory phenotype in the synovial compartment. Peripheral blood NK cells from RA donors are closer to normal distribution but show elevated CD69 from chronic activation. For programs studying NK regulation of autoimmune inflammation, RA-derived NK cells provide the disease-relevant starting phenotype.
KIR Genotyping: The Variable That Makes or Breaks Allogeneic NK Programs
KIR genotyping should be completed before committing to a donor for any allogeneic NK expansion program. The key variables:
KIR haplotype A vs. B: Haplotype A donors express inhibitory KIRs predominantly (KIR2DL1, 2DL2/3, 3DL1/2). Haplotype B donors express additional activating KIRs (KIR2DS1, 2DS2, 2DS3, 2DS4, 2DS5) and produce NK cells with broader activating receptor repertoires. For allogeneic NK programs, haplotype B donors are generally preferred for their activating potential against tumors.
KIR:HLA licensing: Licensed NK cells (those whose inhibitory KIRs are educated by self HLA) are more cytotoxic when they encounter missing-self targets than unlicensed NK cells. Selecting a donor with KIR:HLA combinations relevant to your target patient HLA profile maximizes alloreactive killing in preclinical models.
OrganaBio documents KIR genotype on leukopak lot release certificates — the only supplier that provides this data as a standard deliverable. Contact the scientific team to discuss donor selection by KIR haplotype, HLA type, or disease indication for your NK expansion program.
